New paper from the GCoVS project focussed on GBS validation

A new paper from the VAC4EU network was published in Vaccine as part of the Global COVID Vaccine Safety (GCoVS) project, an initiative coordinated by the Global Vaccine Data Network (GVDN) with extensive involvement from VAC4EU. The authors describe how they estimated the Positive Predictive Value (PPV) of Guillain–Barré syndrome (GBS) across several data sources from our network. VAC4EU played a key role in enabling European participation in this work, which demonstrates the impact of coordinated case validation across multiple real-world data sources and global collaboration. The research also highlights that Brighton Collaboration criteria and in-hospital medical records are essential for accurate GBS validation, as diagnostic certainty improved significantly when cases were identified through hospital data.